June 22, 2015 – The Cooley’s Anemia Foundation is accepting applications from individuals with thalassemia for the 2015 CAF ApoPharma Distinguished Scholar Award. The CAF-ApoPharma Distinguished Scholar Award, which was established last year, is made possible through a grant from pharmaceutical manufacturer ApoPharma. CAF will award up to two scholarships to a U.S. citizen(s) with a clinically significant […]
April 12, 2013 – The Cooley’s Anemia Foundation is pleased to announce the receipt of an unrestricted educational grant in the amount of $100,000 from ApoPharma. This money will be used to support a range of CAF programs and services, including major sponsorship of the upcoming CAF 2013 Patient~Family Conference in Philadelphia on June 28-30. […]
January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]
March 15, 2012 – Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and […]
December 5, 2011 – The oral chelator Ferriprox, recently approved by the U.S. Food and Drug Administration, is available to U.S. patients as of today (December 5, 2011). The drug’s manufacturer, ApoPharma, has set up a system whereby all U.S. patients who have been receiving Ferriprox under a Treatment IND program (also called “compassionate use”) […]
September 20, 2011 – FerroKin BioSciences announced on September 19 that the first dose has been administered in an international Phase 2 study of FBS0701, a novel once-daily oral iron chelator in development for the treatment of transfusional iron overload. This is an Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, […]
September 10, 2010 – FerroKin BioSciences has announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701. “We are excited about the potential of FBS0701 in treating […]
May 11, 2010 – CAF has been notified that a second pharmacuetical company, APP Pharmaceuticals, has begun manufacturing the generic form of the iron chelator deferoxamine mesylate. If you wish to receive the brand name form of deferoxamine (Desferal) rather than the generic form, please make sure that your doctor writes “DAW” (Dispense As Written) on […]
November 30, 2009 – FerroKin BioSciences, Inc. has announced a Phase 1B trial to study the safety and pharmacology of its new oral iron chelator, FBS0701. A total of 16 patients will be enrolled in the study at centers in the U.S., Australia and Italy. Eligibility In general, patients can qualify for […]
March 10, 2009 – CAF would like to make patients aware of a new program offered by Novartis that may reduce your Exjade prescription copayments. This program –The Exjade ScriptAssist Program – provides an opportunity for patients to save up to $900 on their Exjade prescription copayments. The Exjade ScriptAssist Program will run through May 31, […]
